Combination Therapies Designed to Activate the Body’s Own T-cells to Fight Cancer
Our pipeline is focused on T-cell activation and co-stimulation as well as dual-acting immunotherapies that incorporate a T-cell activator and a T-cell co-stimulator into a single injection to offer the potential benefits of combination immunotherapy without the need for multiple, independent biologic products.
| Combination Therapies | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | Comments |
|---|---|---|---|---|---|---|---|
HS-110(viagenpumatucel-L) |
NSCLC |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
Market Phase not started
|
ImPACT® activation technology in combination with nivolumab and other checkpoint inhibitors TBA |
HS-130(viagenpumatucel-L) |
NSCLC |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
ComPACT™ activation technology in combination with checkpoint inhibitors TBA |
| Co-Stimulators | |||||||
PTX-35(viagenpumatucel-L) |
TBA |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
Humanized monoclonal antibody, functional agonist of human TNFRSF25 |